BMC pulmonary medicine
May 22, 2026
1 min readIP Score 10/10
A rare immune-related adverse event of pleural effusion after tislelizumab for non-small cell lung cancer: a case report and literature review.
Wang M; Dai X; Li Z
Abstract
BACKGROUND: Tislelizumab, a specific immune checkpoint inhibitor (ICI) targeting the programmed death protein-1 (PD-1) receptor, represents a novel immunotherapeutic approach for non-small cell lung cancer and has shown promising therapeutic potential. With the increasing clinical use of ICIs, immune-related adverse events (irAEs), including pneumonitis, thyroiditis, and pancreatitis, have been widely recognized. However, pleuritis presenting as pleural effusion (PE) in patients treated with tislelizumab has not yet been reported. CASE PRESENTATION: Here, we report the case of a 60-year-old man with primary lung squamous cell carcinoma who developed a new-onset PE. The patient had previously received treatment with tislelizumab, cisplatin, nab-paclitaxel, and radiotherapy. Notably, he had not received any systemic treatment during the six months preceding the onset of PE. Repeated thoracocenteses showed no malignant cells in the pleural fluid. Further evaluation, including medical thoracoscopy, showed no evidence of malignancy or radiation-induced pleuritis. Additionally, the PE was successfully controlled after corticosteroid therapy. CONCLUSION: This case suggests that late-onset PE may represent a rare form of irAE associated with ICIs and highlights the importance of continued monitoring for delayed irAEs during long-term tumor immunotherapy.
This case highlights the diagnostic and management challenges of refractory multisystem sarcoidosis progressing over a two-year period despite advanced biologic therapy.
Clinicians should note that the presence of targetable mutations in non-small cell lung cancer with malignant pleural disease is not associated with improved survival, based on the findings from this study.
Shape-sensing robotic-assisted bronchoscopy achieved a strict diagnostic yield of 70.2% with a low pneumothorax rate of 3.3%, demonstrating that earlier tissue diagnosis of very small pulmonary nodules is feasible and safe for clinical practice.
Up nextJournal of Thoracic DiseaseOct 30, 2026Read
This study introduces ultrasound-guided trans-cannula cryobiopsy of supraclavicular lymph nodes as a novel superficial lymph node approach for tissue acquisition in 10 consecutive patients, though specific numeric success or safety results were not provided in the abstract.
Active infection is not an absolute contraindication to endobronchial valve placement, but positive pressure ventilation significantly increases clinical failure odds with an aOR of 3.00 at P < 0.001.